Abstract 274P
Background
Index tumors are recognized as the most aggressive prostate tumors; however, their clinical implications remain unclear. This study aimed to investigate the occurrence of index tumor localization based on zonal origin and explore the impact of these locations on the prognosis after radical prostatectomy among patients with negative surgical margins.
Methods
In this retrospective, single-center study, a cohort of 1,109 consecutive patients who underwent radical prostatectomy was analyzed. The index tumor was defined as the largest tumor within the prostate gland. Localization was determined using McNeal's zonal origin classification on whole-mount sections. Kaplan-Meier survival curves were employed to assess biochemical recurrence (BCR)-free survival. Univariate and multivariate Cox proportional hazards analyses were conducted to identify predictive factors for early BCR (within 1 year).
Results
Among the 621 patients with negative surgical margins and no adjuvant therapy, index tumors were localized in the transitional zone in 191 patients (30.8%), the peripheral zone in 399 patients (64.3%), and the central zone in 31 patients (5.0%). A total of 22 patients (3.5%) experienced early BCR, and 70 patients (11.2%) experienced overall BCR during a median follow-up period of 61.7 months. Based on index tumor location, the early BCR-free rates were 99.5%, 95.7%, and 83.3% for the transitional, peripheral, and central zones, respectively. Multivariate analysis identified the index tumor in the central zone as an independent predictor of early BCR with negative surgical margins following radical prostatectomy, followed by the pathological grade of the prostatectomy specimen, index tumor in the peripheral zone, and a high prostate-specific antigen level.
Conclusions
This study examined the significance of index tumor location among patients with negative surgical margins after radical prostatectomy. Notably, index tumors situated in the central zone, although infrequent, emerged as the most robust predictors of early BCR. These findings may prompt urologists and patients to reconsider their therapeutic strategies for prostate cancer management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract